The efficacy and safety of canagliflozin across racial groups in patients with type 2 diabetes mellitus

References

• International Diabetes Federation. IDF Diabetes Atlas, Sixth edition, 2013. Available at: http://www.idf.org/sites/default/files/EN_6E_Atlas_Exec_Sum_1.pdf [Last accessed 8 January 2015]
   Google Scholar
• Kanaya AM, Herrington D, Vittinghoff E, et al. Understanding the high prevalence of diabetes in U.S. South Asians compared with four racial/ethnic groups: the MASALA and MESA studies. Diabetes Care 2014;37:1621-8
   PubMed Web of Science ®Google Scholar
• Riste L, Khan F, Cruickshank K. High prevalence of type 2 diabetes in all ethnic groups, including Europeans, in a British inner city: relative poverty, history, inactivity, or 21st century Europe? Diabetes Care 2001;24:1377-83
   PubMed Web of Science ®Google Scholar
• Dagogo-Jack S. Ethnic disparities in type 2 diabetes: pathophysiology and implications for prevention and management. J Natl Med Assoc 2003;95:774-9
   PubMed Web of Science ®Google Scholar
• Gaillard TR, Osei K. Racial disparities in the pathogenesis of type 2 diabetes and its subtypes in the African diaspora: a new paradigm. J Racial Ethnic Health Disparities 2015; doi: 10.1007/s40615-015-0121-z. Published online 16 May 2015
   PubMedGoogle Scholar
• Selvin E, Steffes MW, Ballantyne CM, et al. Racial differences in glycemic markers: a cross-sectional analysis of community-based data. Ann Intern Med 2011;154:303-9
   PubMed Web of Science ®Google Scholar
• Herman WH, Ma Y, Uwaifo G, et al. Differences in A1C by race and ethnicity among patients with impaired glucose tolerance in the Diabetes Prevention Program. Diabetes Care 2007;30:2453-7
   PubMed Web of Science ®Google Scholar
• Ziemer DC, Kolm P, Weintraub WS, et al. Glucose-independent, black–white differences in hemoglobin A1c levels: a cross-sectional analysis of 2 studies. Ann Intern Med 2010;152:770-7
   PubMed Web of Science ®Google Scholar
• Herman WH, Dungan KM, Wolffenbuttel BH, et al. Racial and ethnic differences in mean plasma glucose, hemoglobin A1c, and 1,5-anhydroglucitol in over 2000 patients with type 2 diabetes. J Clin Endocrinol Metab 2009;94:1689-94
   PubMed Web of Science ®Google Scholar
• Mostafa SA, Davies MJ, Webb DR, et al. Independent effect of ethnicity on glycemia in South Asians and white Europeans. Diabetes Care 2012;35:1746-8
   PubMed Web of Science ®Google Scholar
• Wolffenbuttel BH, Herman WH, Gross JL, et al. Ethnic differences in glycemic markers in patients with type 2 diabetes. Diabetes Care 2013;36:2931-6
   PubMed Web of Science ®Google Scholar
• Lynch CP, Williams JL, Reid J, et al. Racial/ethnic differences in multiple diabetes outcomes in patients with type 2 diabetes in the southeastern United States. Ethn Dis 2014;24:189-94
   PubMed Web of Science ®Google Scholar
• Lopez JM, Bailey RA, Rupnow MF, Annunziata K. Characterization of type 2 diabetes mellitus burden by age and ethnic groups based on a nationwide survey. Clin Ther 2014;36:494-506
   PubMed Web of Science ®Google Scholar
• Hu FB. Globalization of diabetes: the role of diet, lifestyle, and genes. Diabetes Care 2011;34:1249-57
   PubMed Web of Science ®Google Scholar
• Premanath M, Basavanagowdappa H, Mahesh M, Suresh M. Correlation of abdominal adiposity with components of metabolic syndrome, anthropometric parameters and Insulin resistance, in obese and non obese, diabetics and non diabetics: a cross sectional observational study. (Mysore Visceral Adiposity in Diabetes Study). Indian J Endocrinol Metab 2014;18:676-82
   PubMedGoogle Scholar
• Banerji MA, Faridi N, Atluri R, et al. Body composition, visceral fat, leptin, and insulin resistance in Asian Indian men. J Clin Endocrinol Metab 1999;84:137-44
   PubMed Web of Science ®Google Scholar
• Wright EM, Hirayama BA, Loo DF. Active sugar transport in health and disease. J Intern Med 2007;261:32-43
   PubMed Web of Science ®Google Scholar
• Musso G, Gambino R, Cassader M, Pagano G. A novel approach to control hyperglycemia in type 2 diabetes: sodium glucose co-transport (SGLT) inhibitors: systematic review and meta-analysis of randomized trials. Ann Med 2012;44:375-93
   PubMed Web of Science ®Google Scholar
• Matthews D, Zinman B, Tong C, et al. Glycemic efficacy of canagliflozin (CANA) is largely independent of baseline beta-cell function or insulin sensitivity [abstract 1096-P]. Diabetes 2014;63(Suppl 1):A285
   Google Scholar
• Bakker LE, Sleddering MA, Schoones JW, et al. Pathogenesis of type 2 diabetes in South Asians. Eur J Endocrinol 2013;169:R99-114
   PubMed Web of Science ®Google Scholar
• Bacha F, Gungor N, Lee S, Arslanian SA. Type 2 diabetes in youth: are there racial differences in β-cell responsiveness relative to insulin sensitivity? Pediatr Diabetes 2012;13:259-65
   PubMed Web of Science ®Google Scholar
• Bogardus C, Tataranni PA. Reduced early insulin secretion in the etiology of type 2 diabetes mellitus in Pima Indians. Diabetes 2002;51(Suppl 1):S262-4
   Google Scholar
• Stenlöf K, Cefalu WT, Kim KA, et al. Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise. Diabetes Obes Metab 2013;15:372-82
   PubMed Web of Science ®Google Scholar
• Lavalle-González FJ, Januszewicz A, Davidson J, et al. Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trial. Diabetologia 2013;56:2582-92
   PubMed Web of Science ®Google Scholar
• Wilding JP, Charpentier G, Hollander P, et al. Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sulphonylurea: a randomised trial. Int J Clin Pract 2013;67:1267-82
   PubMed Web of Science ®Google Scholar
• Forst T, Guthrie R, Goldenberg R, et al. Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes on background metformin and pioglitazone. Diabetes Obes Metab 2014;16:467-77
   PubMed Web of Science ®Google Scholar
• Cefalu WT, Leiter LA, Yoon KH, et al. Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial. Lancet 2013;382:941-50
   PubMed Web of Science ®Google Scholar
• Neal B, Perkovic V, de Zeeuw D, et al. Rationale, design, and baseline characteristics of the Canagliflozin Cardiovascular Assessment Study (CANVAS) – a randomized placebo-controlled trial. Am Heart J 2013;166:217-33
   PubMed Web of Science ®Google Scholar
• Fulcher G, Matthews D, Perkovic V, et al. Canagliflozin (CANA) in subjects with type 2 diabetes mellitus (T2DM) inadequately controlled on sulfonylurea (SU) monotherapy: a CANVAS substudy [abstract 1124-P]. Diabetes 2013;62(Suppl 1):A292
   Google Scholar
• Rosenstock J, Davies M, Dumas R, et al. Effects of canagliflozin added on to basal insulin +/− other antihyperglycemic agents in type 2 diabetes [abstract 1084-P]. Diabetes 2013;62(Suppl 1):A280
   Google Scholar
• Inagaki N, Kondo K, Yoshinari T, Kuki H. Efficacy and safety of canagliflozin alone or as add-on to other oral antihyperglycemic drugs in Japanese patients with type 2 diabetes: A 52-week open-label study. J Diabetes Investig 2015;6:210-18
   PubMed Web of Science ®Google Scholar
• Rosenwasser RF, Sultan S, Sutton D, et al. SGLT-2 inhibitors and their potential in the treatment of diabetes. Diabetes Metab Syndr Obes 2013;6:453-67
   PubMedGoogle Scholar
• Nyirjesy P, Sobel JD, Fung A, et al. Genital mycotic infections with canagliflozin, a sodium glucose co-transporter 2 inhibitor, in patients with type 2 diabetes mellitus: a pooled analysis of clinical studies. Curr Med Res Opin 2014;30:1109-19
   PubMed Web of Science ®Google Scholar
• Johnsson KM, Ptaszynska A, Schmitz B, et al. Urinary tract infections in patients with diabetes treated with dapagliflozin. J Diabetes Complications 2013;27:473-8
   PubMed Web of Science ®Google Scholar
• Ahrén B, Mathieu C, Bader G, et al. Efficacy of vildagliptin versus sulfonylureas as add-on therapy to metformin: comparison of results from randomised controlled and observational studies. Diabetologia 2014;57:1304-7
   PubMed Web of Science ®Google Scholar
• Davidson JA, Lacaya LB, Jiang H, et al. Impact of race/ethnicity on the efficacy and safety of commonly used insulin regimens: a post hoc analysis of clinical trials in type 2 diabetes mellitus. Endocr Pract 2010;16:818-28
   PubMed Web of Science ®Google Scholar
• TODAY Study Group, Zeitler P, Hirst K, et al. A clinical trial to maintain glycemic control in youth with type 2 diabetes. N Engl J Med 2012;366:2247-56
   PubMed Web of Science ®Google Scholar
• Kim YG, Hahn S, Oh TJ, et al. Differences in the glucose-lowering efficacy of dipeptidyl peptidase-4 inhibitors between Asians and non-Asians: a systematic review and meta-analysis. Diabetologia 2013;56:696-708
   PubMed Web of Science ®Google Scholar